drugset / Trial / NCT01831505
Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents
Phase 1
Completed
4 enrolled
Presage Biosciences
Fred Hutchinson Cancer Center · collabNational Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelBasic science
Summary
Many cancer patients are prescribed drugs to which their cancer is already resistant - and thus suffer toxicity with no potential for benefit. Previous attempts to assess chemoresistance or sensitivity in vitro have failed. This is a feasibility study in human patients with newly diagnosed or recurrent lymphoma to determine how human cancerous lymph nodes in situ respond to standard of care therapeutics precisely microinjected with the CIVO(tm) microdosing system.
Timeline
- Start
- 2012-11
- Primary completion
- 2013-07
- Completion
- 2013-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | — | Other |
| Subject | Doxorubicin | Other / unclassified | — | Other |
| Subject | Prednisolone | Other / unclassified | — | Other |
| Subject | Rituximab | Monoclonal antibody | — | Other |
| Subject | Vincristine | Small molecule | — | Other |